Abstracts tagged "Fracture"

Abstract Number: 0345 • ACR Convergence 2025
Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Hashem Cheema¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe bay NHS foundation trust, Manchester, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Low socioeconomic status is associated with.an increase in osteoporosis and fracture risk respectively. A multitude of factors have been proposed including income, educational attainment…
Abstract Number: 2114 • ACR Convergence 2025
Development of a Fracture Prediction Model for Patients Aging with HIV
Evelyn Hsieh¹, Terrence E. Murphy², Baylah Tessier-Sherman³, Linda Leo-Summers³, Farah Kidwai-Khan⁴, Samah Fodeh⁵, Rixin Wang⁶, Barbara Gulanski³, Michael T. Yin⁷, Melissa Skanderson⁸, Cynthia Brandt⁹, Amy C. Justice⁴ and Julie Womack¹⁰, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine / VA Connecticut Healthcare System, New Haven, CT, ²Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, ³Department of Internal Medicine, Yale School of Medicine, New Haven, CT, ⁴Department of Internal Medicine, Yale School of Medicine / VA Connecticut Healthcare System, New Haven, CT, ⁵Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, ⁶Department of Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, CT, ⁷Columbia University Irving Medical Center, New York, NY, ⁸VA Connecticut Healthcare System, West Haven, CT, ⁹Department of Biomedical Informatics & Data Science, Yale School of Medicine / VA Connecticut Healthcare System, New Haven, CT, ¹⁰Yale School of Nursing / VA Connecticut Healthcare System, Orange, CT
Background/Purpose: Fragility fractures are a critical outcome for people ageing with HIV (PAH). Studies demonstrate higher prevalence, incidence, and earlier onset than for the general…
Abstract Number: 0347 • ACR Convergence 2025
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Kabyar Cho¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Coeliac disease (CD) is an autoimmune disease, which has been widely reported to be associated with reduced bone mineral density (BMD), leading to an…
Abstract Number: 2115 • ACR Convergence 2025
METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
François ROBIN¹, Roba Ghossan², Nadia Mehsen-Cetre³, Louise Triquet¹, Guillaume LARID⁴, Guillaume Coiffier⁵, Marine Mina⁶, Marie-Eva Pickering⁷, Claire Barthe⁸, Julien Paccou⁹, Julien Herman¹⁰, Emmanuel Massy¹¹, Isabelle Roitg¹², Martine Branquet¹³, Julien Lasnier Siron³, Manon Guillouard¹⁴, Camille Desmonet Trousset¹⁵, Aurore Aubrun¹⁶, Bertrand Godfrin¹⁷, Jean-Philippe Hauzeur¹⁸, Emmanuel Chatelus¹⁹, Eugénie Koumakis², Jean-Louis Legrand²⁰, Thierry Schaeverbeke³, Alexia Leloix¹, Maeva Masson²¹, Julia Nicolau¹⁵, Charles Ghiringhelli²², Marijke Decrock¹², Durel Cécile-Audrey²³, Béatrice Bouvard²⁴, Bernard Cortet⁹, Charlotte Casadepax-Soulet²⁵, Olivier Malaise⁶, Rose Marie Javier²⁶, Karine Briot² and Pascal Guggenbuhl¹, ¹Rennes University Hospital, Rennes, France, ²APHP, Paris, France, ³Bordeaux University Hospital, Bordeaux, France, ⁴Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ⁵Dinan Hospital, Dinan, France, ⁶Liege University Hospital, Liège, Belgium, ⁷Clermon-Ferrand University Hospital, Clermont-Ferrand, France, ⁸Clinique Tivoli Ducos, Bordeaux, France, ⁹Lille University Hospital, Lille, France, ¹⁰La Roche Sur Yon Hospital, La Roche-sur-Yon, France, ¹¹Lyon University Hospital, Lyon, France, ¹²Perpignan Hospital, Perpignan, France, ¹³Ploemeur Rheumatology Liberal Structure, Ploemeur, France, ¹⁴Aurillac Hospital, Aurillac, France, ¹⁵Dieppe Hospital, Dieppe, France, ¹⁶Nice Rheumatology Liberal Stucture, Nice, France, ¹⁷St Gaudens Rheumatology Liberal Structure, St Gaudens, France, ¹⁸Liege University Hospital, Liege, Belgium, ¹⁹Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ²⁰Arras Hospital, Arras, France, ²¹Toulouse University Hospital, Toulouse, France, ²²Pauillac Rheumatology Liberal Structure, Pauillac, France, ²³Saint Joseph Saint Luc Hospital, Lyon, France, ²⁴Angers University Hospital, Angers, France, ²⁵West Reunion Hospital, Saint Paul, France, ²⁶Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Methotrexate-induced osteopathy is a rare condition. The clinical presentation is often typical, associating lower limb involvement with metaphyseal bone fractures/cracks, mainly of the tibia…
Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
MARIA DEL CARMEN ORTEGA DE LA O¹, Laura Gonzalez Hombrado², Marina Salido Olivares³, Carolina Marin⁴, Angel Aragon⁵, Celia arconada⁶, Maria Carmen Ortega de la O⁷, Alvaro Garcia⁸, elisabeth Castañeda⁹, Patricia Castro Perez¹⁰, alberto diaz Oca¹¹ and Eva Andres Esteban¹², ¹HOSPITAL UNIVERSITARIO GETAFE, GETAFE, Madrid, Spain, ²Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Madrid, Spain, ⁴Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁵Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain, ⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁷Hospital Universitario Getafe, Madrid, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez, Madrid, Spain, ⁹Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁰Hospital de Getafe, Madrid, Madrid, Spain, ¹¹Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain, ¹²Universidad Rey Juan Carlos, Fuenlabrada, Spain
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…
Abstract Number: 2116 • ACR Convergence 2025
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Giovanni Adami¹, Mariana Diz Lopes², Martina Tinelli², Angela Bonalumi², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Bone damage is a key feature of multiple myeloma (MM). Romosozumab (ROMO), a sclerostin inhibitor, has dual anabolic and antiresorptive properties and may offer…
Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Marshall Weber¹, William Obremskey², Jared Huling³, Nitya Shah³, Emily Budde⁴, Zhiping Huo⁴, Reside Jacob⁴, Brinda Basida¹, Colton Hoffer¹, Binni Makkar⁵ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²Vanderbilt University, Nashville, TN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴Center of Innovation for Complex Chronic Healthcare, Washington DC, DC, ⁵University of Kentucky, Lexington, KY
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…
Abstract Number: 2119 • ACR Convergence 2025
Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Winnie Liu¹, Jeffrey Curtis², Lars Folkestad³, Emily Holladay⁴, Jingyi zhang², Shanette Daigle⁵, Ye Liu², Fenglong Xie⁶ and Eric Orwoll¹, ¹Oregon Health and Science University, Portland, OR, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Southern Denmark, Odense, Denmark, Odense, Denmark, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility caused by mutations related to type 1 collagen biosynthesis. Fractures are a…
Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…
Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 0354 • ACR Convergence 2025
Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
Rachel Elam¹, Petra Buzkova², Howard Fink³, Joshua Barzilay⁴, Eric Roseen⁵, Jane Cauley⁶, John Robbins⁷, Laura Carbone¹, Gina Lovasi⁸ and Kenneth Mukamal⁹, ¹Augusta University, Augusta, GA, ²University of Washingon, Seattle, WA, ³University of Minnesota, Minneapolis, MN, ⁴Kaiser Permanente of Georgia, Atlanta, GA, ⁵Boston University, Boston, MA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of California Davis, Davis, CA, ⁸Drexel University, Philadelphia, PA, ⁹Beth Israel Deaconess Medical Center, Brookline, MA
Background/Purpose: Higher physical activity is linked to reduced fracture risk in older adults, especially for hip fractures. Emerging evidence demonstrates a potential role for the…
Abstract Number: 2479 • ACR Convergence 2025
REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.
Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Marco Di Paola¹, Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Andrea Claudio Ştețco⁷, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Systemic sclerosis (SS) is a rare connective tissue disorder characterized by progressive fibrosis of the skin and internal organs, including lungs, heart and kidneys.…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
Abstract Number: 2621 • ACR Convergence 2025
Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
MAXIME AUROUX¹, MERCIER-GUERY Alexandre¹, PIOT Anne², MERLE Blandine³, PRORIOL Mathilde¹, FONTANGES Elisabeth¹, DUVERT Florence¹, Eric LESPESSAILLES⁴ and CHAPURLAT Roland¹, ¹Hospices Civils de Lyon, LYON, France, ²Centre Hospitalier Lucien Hussel, VIENNE, France, ³INSERM U¹⁰³³, LYON, France, ⁴University Hospital of Orléans, Orleans, France
Background/Purpose: Erosive hand osteoarthritis (ErHOA) is a severe form of hand osteoarthritis (HOA) characterized by greater inflammation and higher burden of disease. In this more…
Abstract Number: 1313 • ACR Convergence 2025
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Jonathan Barnes¹, Hamzah Amin² and marwan Bukhari³, ¹Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…

1
2
3
…
8
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].